dalteparin

Home
Ligands
dalteparin

GtoPdb Ligand ID: 6803

Synonyms: dalteparin sodium | Fragmin®

dalteparin is an approved drug (FDA (1994))

Comment: An antithrombin-III activator. Since this drug is a mixture of hydrolysed fragments of porcine herparin, a chemical structure is not shown.

View more information in the IUPHAR Pharmacology Education Project: dalteparin

No information available.

No information available.

Summary of Clinical Use
Used as a prophylaxis for deep-vein thrombosis and pulmonary embolisms in various at-risk groups of patients (e.g. those undergoing general surgery, with acute medical conditions, severely restricted mobility or undergoing hemodialysis or hemofiltration). In May 2019, the FDA approved dalteparin's use in paediatric patients ≥1 month of age, to reduce the recurrence of symptomatic venous thromboembolism (VTE), based on findings from clinical trial NCT00952380. This was the first FDA approval of a drug to manage VTE in paediatric patients.

Summary of Clinical Use

Used as a prophylaxis for deep-vein thrombosis and pulmonary embolisms in various at-risk groups of patients (e.g. those undergoing general surgery, with acute medical conditions, severely restricted mobility or undergoing hemodialysis or hemofiltration). In May 2019, the FDA approved dalteparin's use in paediatric patients ≥1 month of age, to reduce the recurrence of symptomatic venous thromboembolism (VTE), based on findings from clinical trial NCT00952380. This was the first FDA approval of a drug to manage VTE in paediatric patients.

Mechanism Of Action and Pharmacodynamic Effects
A low molecular weight heparin (LMWH, MW 2000-9000 Da), anticoagulant

Mechanism Of Action and Pharmacodynamic Effects

A low molecular weight heparin (LMWH, MW 2000-9000 Da), anticoagulant

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT00952380	Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients	Phase 2 Interventional	Pfizer